U.S. Markets close in 4 hrs 9 mins

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
36.58-3.18 (-8.00%)
As of 11:50AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close39.76
Open39.43
Bid37.04 x 800
Ask37.18 x 1000
Day's Range36.53 - 39.76
52 Week Range24.15 - 94.17
Volume97,297
Avg. Volume309,790
Market Cap3.027B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est82.00
  • Atea Pharmaceuticals (AVIR) Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    Atea Pharmaceuticals (AVIR) Sees Hammer Chart Pattern: Time to Buy?

    Atea Pharmaceuticals (AVIR) has been struggling lately, but the selling pressure may be coming to an end soon

  • Reuters

    UPDATE 1-Roche looking for new place to test COVID-19 pill after cases plummet in UK

    Roche is looking for another location to carry out trials of its pill to fight COVID-19, after plummeting case numbers in Britain made it difficult to find enough patients for its study there, the Swiss drugmaker said on Wednesday. Roche and Boston-based partner Atea Pharmaceuticals are hoping their AT-527 pill could offer an anti-viral therapy to treat COVID-19 patients that would be easier to administer and cheaper than other prospective treatments, such as antibody cocktails or Gilead Science's remdesivir. In an interview in Swiss media in early March, Roche Chairman Christoph Franz had offered the tantalizing prospect of data on AT-527 "within the next weeks", saying he dreamed of being able to fight the pandemic with a pill by year's end.

  • Atea Pharmaceuticals (AVIR) Is in Oversold Territory: What's Next?
    Zacks

    Atea Pharmaceuticals (AVIR) Is in Oversold Territory: What's Next?

    Atea Pharmaceuticals (AVIR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock